European cancer monoclonal antibodies market is estimated to grow at a CAGR of 8.0% during the forecast period. The significant prevalence of cancer and increasing cancer research is driving market growth. As per the European Commission, the cancer burden is estimated to have increased to 2.7 million new cases (all kinds, excluding non-melanoma skin cancer) in 2020. This is driving the demand for monoclonal antibodies therapies for cancer therapeutics. It acts as a targeted therapy as they have a particular target on a cancerous cell. However, other monoclonal antibodies work as immunotherapy which makes the immune system respond better that support the body to more potentially find and attack cancer cells. 

Visit for Global Cancer Monoclonal Antibodies Market Report at: https://www.omrglobal.com/industry-reports/cancer-monoclonal-antibodies-market

Some monoclonal antibodies that are available in the European market include Bevacizumab (Avastin), Cetuximab (Erbitux), and alemtuzumab (Campath). Increasing launches of monoclonal antibody biosimilars have also been reported in the region. For instance, in August 2020, Samsung Bioepis Co., Ltd. declared that the European Commission allowed marketing authorization for AYBINTIO (bevacizumab) to treat similar kinds of cancer as reference bevacizumab, including advanced and/or metastatic renal cell cancer (mRCC), non-small cell lung cancer (NSCLC), metastatic carcinoma of the colon or rectum (mCRC), epithelial ovarian, fallopian tube and primary peritoneal cancer, metastatic breast cancer (mBC), and cervical cancer.

European cancer monoclonal antibodies market is segmented based on type and application. Based on type, the market is classified into naked, conjugated, and others. Naked monoclonal antibodies are the most common medications used for the treatment of cancer. Bevacizumab (Avastin), Alemtuzumab (Lemtrada), Cetuximab (Erbitux), Trastuzumab (Herceptin), and MabThera/Rituxan is some naked monoclonal antibody drugs that are commonly used for cancer treatment in the region. Increasing launches of biosimilars of these drugs are providing scope for the availability of cost-effective monoclonal antibody treatment in the region. Based on the application, the market is classified into breast cancer, liver cancer, blood cancer, brain cancer, colorectal cancer, and others. Monoclonal antibodies are expected to find significant application in breast cancer. 

Some prominent players in the market include AstraZeneca plc, Pfizer Inc., F- Hoffman La-Roche AG, Novartis AG, and Mylan N.V. Product launches and partnerships and collaborations are regarded as some potential strategies implemented by the market players to increase their position in the marketplace. For instance, in April 2020, Pfizer Inc. declared the European Commission approval of RUXIENCE (rituximab), a monoclonal antibody (mAb) and biosimilar to MabThera (rituximab), to treat non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), microscopic polyangiitis (MPA), rheumatoid arthritis (RA), pemphigus vulgaris (PV), and granulomatosis with polyangiitis (GPA). The approval of RUXIENCE is a crucial development to treat certain autoimmune conditions and cancers. 

Research Methodology

The market study of the European cancer monoclonal antibodies market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. European Cancer Monoclonal Antibodies Market Research and Analysis by Type
2. European Cancer Monoclonal Antibodies Market Research and Analysis by Application

The Report Covers

• Comprehensive research methodology of the European cancer monoclonal antibodies market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the European cancer monoclonal antibodies market.
• Insights about market determinants which are stimulating the European cancer monoclonal antibodies market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.